Transdermal (Percutaneous) Drug Delivery Systems Market Research Report: by Product (Transdermal Patches, Semisolids), Technology (Electric Current, Iontophoresis, Electroporation, Ultrasound, Microporation), and Application (HRT) — Forecast till 2030

Transdermal (Percutaneous) Drug Delivery Systems Market Overview:

The Transdermal (Percutaneous) Drug Delivery Systems Market is expected to reach USD 45589.02 Million by 2030 at 5.1% CAGR during the forecast period 2022-2030.

Transdermal medication conveyance framework (TDDS) conveys drugs through the skin to foundational course at a foreordained rate and keep up with the compelling fixations clinically over a lengthy period. TDDS likewise called as patches are measurement frames that convey a remedially successful measure of medication through the patients' skin.

Overall developing geriatric populace alongside ascending in the commonness of persistent infections is the main element driving the market development. Likewise, quick mechanical headways in transdermal medication conveyance frameworks and expanding reception of third-age conveyance frameworks are supposed to increase the market development during the gauge time frame. The geriatric populace is more inclined to foster Q fever.

The older populace across the world is on the flood. The World Health Organization (WHO) detailed that the overall populace matured 60 years or more was 962.0 million out of 2017, which is projected to increment to over 2.0 billion by 2050 and further would reach to 3.1 billion by 2100.

In any case, disservices of conveyance frameworks including edema and bothering, normal restrictions of medication passage forced by the skin's impermeability, and absence of bond of the transdermal framework to various skin types are expected to frustrate the market development over the estimate time frame.

Furthermore, drugs that require high blood levels can't be managed through TDDS as it is restricted exclusively to intense particles, those requiring an everyday portion of 10 mg or less, consequently influencing the market development.

The global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, application, and region.

By product, the market has been segmented into transdermal patches and transdermal semisolids. The transdermal patches segment is further categorized into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and microneedle patches. The transdermal semisolids segment is additionally divided into gels, ointments, and sprays. The transdermal patches segment spearheaded the market in 2017 due to its benefits offered such as improved bioavailability, reduced dosing frequency, lower adverse events, enhanced patient compliance (non-invasive nature), painless application, and drug input termination at any point by the removal of the patch.

On the basis of technology, the market has been divided into electric current, iontophoresis, electroporation, ultrasound, microporation, thermal, and others.

Based on application, the market has been categorized into pain management, cardiovascular diseases, hormone replacement therapy, central nervous system disorders, smoking cessation, contraception, and others.

The global transdermal (percutaneous) drug delivery systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The transdermal (percutaneous) drug delivery systems market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European transdermal (percutaneous) drug delivery systems market has been segmented into Western Europe and Eastern Europe. The Western Europe transdermal (percutaneous) drug delivery systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The transdermal (percutaneous) drug delivery systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The transdermal (percutaneous) drug delivery systems market in the Middle East & Africa has been segmented into the Middle East and Africa.

Transdermal Drug Delivery Systems Regional Market Summary

Global Transdermal (Percutaneous) Drug Delivery Systems Market Share (%), by Region, 2017

Source: White Papers, Company Presentations, Annual Reports

Geographically, in 2017, the Americas led the global transdermal (percutaneous) drug delivery systems market due to the presence of major market players (Pfizer Inc., and Johnson & Johnson Services, Inc.) and developed healthcare infrastructure, surging number of research activities related to transdermal drug delivery systems, and comparatively higher adoption of TDDS system in the US and Canada.

Europe would be the second leader in the transdermal (percutaneous) drug delivery systems market owing to phenomenal growth in the pharmaceutical industry coupled with the headquarters of Novartis International AG, Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Boehringer Ingelheim International GmbH, and Allergan plc.

Growing elderly population base coupled with the rising prevalence of chronic diseases such as cardiovascular diseases (CVDs) and chronic pain in India, China, and Japan are likely to support the profitable growth of the Asia-Pacific throughout the forecast period. For instance, the CADI (Coronary Artery Disease among Asian Indians) Research Foundation reported that hypertension is the most prevalent disease in India and the number of people suffering from hypertension in the country was 118.0 million in 2000, which is estimated to reach to 214.0 million by 2025.

The transdermal (percutaneous) drug delivery systems market in the Middle East & Africa would register the modest market growth rate from 2018 to 2023. The increasingly gentrified populations in the Gulf Cooperation Council (GCC) countries and Sub-Saharan African countries, and the development of sophisticated universal healthcare systems in the Middle East are expected to assist in the market growth during next five years.

Transdermal (Percutaneous) Drug Delivery Systems Market, by Product

• 
  Transdermal Patches
  
  
  
  • Drug-In-Adhesive Patches
  
  
  • Matrix Patches
  
  
  • Reservoir Membrane Patches
  
  
  • Microneedle Patches
  
  
  
  


• 
  Transdermal Semisolids
  
  
  
  • Gels
  
  
  • Ointments
  
  
  • Sprays
  
  
  
  

Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology

• Electric Current


• Iontophoresis


• Electroporation


• Ultrasound


• Microporation


• Thermal


• Others

Transdermal (Percutaneous) Drug Delivery Systems Market, by Application

• Pain Management


• Cardiovascular Diseases


• Hormone Replacement Therapy


• Central Nervous System Disorders


• Smoking Cessation


• Contraception


• Others

Transdermal (Percutaneous) Drug Delivery Systems Market, by Region

• 
  Americas
  
  
  
  • 
    North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  


• 
  Europe
  
  
  
  • 
    Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • UK
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Transdermal (Percutaneous) Drug Delivery Systems Market, by Key Players

• Mylan N.V.


• Hisamitsu Pharmaceutical Co., Inc.


• Novartis International AG


• Boehringer Ingelheim International GmbH


• GlaxoSmithKline PLC


• Johnson & Johnson Services, Inc.


• Endo Pharmaceuticals Inc.


• UCB S.A.


• Pfizer Inc.


• Allergan plc


• Actelion Pharmaceuticals Ltd


• Noven Pharmaceuticals, Inc.

Recent Development

In January 2018:

Hisamitsu Pharmaceutical (Japan) sent off ALLESAGA TAPE in the Japanese market.

In July 2018:

UCB (Belgium) got the Import Drug License (IDL) for its transdermal rotigotine fix — NEUPRO from the China Food and Drug Administration (CFDA).

In August 2018:

Luye Pharma (China) consented to an arrangement with Bayer AG (Switzerland) to procure the worldwide freedoms to the Apleek prophylactic transdermal fix.Intended Audience

• Transdermal drug delivery system device manufacturers and suppliers


• Pharmaceutical industries


• Research institutes


• Venture capitalists


• Association and government bodies


• Market research and consulting service providers


• Hospitals and clinics


• Corporate entities